Sandoz Attacks Amgen Over US Enbrel Exclusivity

Firm Claims $1bn+ In Lost Biosimilar Sales As It Attacks ‘Scheming’ Originator

 
• By Dave Wallace
  
Sandoz has launched an antitrust lawsuit attacking Amgen (Shutterstock)

More from Legal & IP

More from Business